How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
59
AXSM Quote, Financials, Valuation and Earnings
Last price:
$184.34
Seasonality move
:
17.49%
Day range:
$180.56 - $188.00
52-week range:
$86.99 - $191.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.16x
P/B ratio:
125.99x
Volume:
745.8K
Avg. volume:
764.8K
1-year change:
69.27%
Market cap:
$9.3B
Revenue:
$385.7M
EPS (TTM):
-$4.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$191.4M | -$0.75 | 57.25% | -43.6% | $212.94 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$293M | $0.14 | 13.72% | 13.07% | $31.05 |
|
CORT
Corcept Therapeutics, Inc.
|
$255.3M | $0.30 | 27.74% | -71.78% | $94.20 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
GILD
Gilead Sciences, Inc.
|
$7.7B | $1.84 | 4.32% | 94.73% | $138.03 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$184.25 | $212.94 | $9.3B | -- | $0.00 | 0% | 16.16x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$25.13 | $31.05 | $4.3B | 16.17x | $0.00 | 0% | 4.04x |
|
CORT
Corcept Therapeutics, Inc.
|
$39.87 | $94.20 | $4.2B | 45.56x | $0.00 | 0% | 6.43x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
GILD
Gilead Sciences, Inc.
|
$141.95 | $138.03 | $176.1B | 21.99x | $0.79 | 2.23% | 6.14x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.54 | $13.63 | $445.6M | -- | $0.00 | 0% | 2.09x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.062 | 3.58% | 1.45x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.825 | 1.52% | 2.70x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.024 | 18.1% | 1.16x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Axsome Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AXSM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 25.76%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About AXSM or ACAD?
Axsome Therapeutics, Inc. has a consensus price target of $212.94, signalling upside risk potential of 15.57%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.05 which suggests that it could grow by 23.57%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.16 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is AXSM or ACAD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.083%.
-
Which is a Better Dividend Stock AXSM or ACAD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or ACAD?
Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 16.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.16x versus 4.04x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M
-
Which has Higher Returns AXSM or CORT?
Corcept Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 9.32%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About AXSM or CORT?
Axsome Therapeutics, Inc. has a consensus price target of $212.94, signalling upside risk potential of 15.57%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $94.20 which suggests that it could grow by 136.27%. Given that Corcept Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.16 1 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is AXSM or CORT More Risky?
Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock AXSM or CORT?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or CORT?
Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 45.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.16x versus 6.43x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M CORTCorcept Therapeutics, Inc.6.43x 45.56x $207.6M $19.4M
-
Which has Higher Returns AXSM or FOLD?
Amicus Therapeutics, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 10.24%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About AXSM or FOLD?
Axsome Therapeutics, Inc. has a consensus price target of $212.94, signalling upside risk potential of 15.57%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Axsome Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.16 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is AXSM or FOLD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock AXSM or FOLD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or FOLD?
Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.16x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns AXSM or GILD?
Gilead Sciences, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of 39.21%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About AXSM or GILD?
Axsome Therapeutics, Inc. has a consensus price target of $212.94, signalling upside risk potential of 15.57%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $138.03 which suggests that it could fall by -2.76%. Given that Axsome Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Axsome Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.16 1 0 GILDGilead Sciences, Inc.17 7 0 -
Is AXSM or GILD More Risky?
Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.
-
Which is a Better Dividend Stock AXSM or GILD?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.23% to investors and pays a quarterly dividend of $0.79 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or GILD?
Axsome Therapeutics, Inc. quarterly revenues are $171M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 21.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.16x versus 6.14x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M GILDGilead Sciences, Inc.6.14x 21.99x $7.8B $3.1B
-
Which has Higher Returns AXSM or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -27.62% compared to Axsome Therapeutics, Inc.'s net margin of -40.15%. Axsome Therapeutics, Inc.'s return on equity of -327.97% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About AXSM or VNDA?
Axsome Therapeutics, Inc. has a consensus price target of $212.94, signalling upside risk potential of 15.57%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 80.7%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXSMAxsome Therapeutics, Inc.16 1 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is AXSM or VNDA More Risky?
Axsome Therapeutics, Inc. has a beta of 0.438, which suggesting that the stock is 56.163% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock AXSM or VNDA?
Axsome Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXSM or VNDA?
Axsome Therapeutics, Inc. quarterly revenues are $171M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Axsome Therapeutics, Inc.'s net income of -$47.2M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Axsome Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics, Inc. is 16.16x versus 2.09x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M VNDAVanda Pharmaceuticals, Inc.2.09x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
